These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 38410417)
1. Can Lipid-Lowering Drugs Reduce the Risk of Cholelithiasis? A Mendelian Randomization Study. Dong H; Chen R; Xu F; Cheng F Clin Epidemiol; 2024; 16():131-141. PubMed ID: 38410417 [TBL] [Abstract][Full Text] [Related]
2. HMGCR as a promising molecular target for therapeutic intervention in aortic aneurisms: a mendelian randomization study. Zheng PF; Zheng ZF; Liu ZY; He J; Rong JJ; Pan HW Nutr Metab (Lond); 2024 Oct; 21(1):81. PubMed ID: 39402528 [TBL] [Abstract][Full Text] [Related]
3. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. Huang W; Xiao J; Ji J; Chen L Elife; 2021 Dec; 10():. PubMed ID: 34866576 [TBL] [Abstract][Full Text] [Related]
4. Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study. Gao X; Luo W; Qu L; Yang M; Chen S; Lei L; Yan S; Liang H; Zhang X; Xiao M; Liao Y; Lee AP; Zhou Z; Chen J; Zhang Q; Wang Y; Xiu J Eur J Prev Cardiol; 2024 Jul; 31(9):1132-1140. PubMed ID: 38302118 [TBL] [Abstract][Full Text] [Related]
5. Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study. Wang R; Zhao J; Li L; Huo Y J Hypertens; 2024 Apr; 42(4):727-734. PubMed ID: 38230624 [TBL] [Abstract][Full Text] [Related]
6. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study. Qiao L; Lv S; Meng K; Yang J Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113 [TBL] [Abstract][Full Text] [Related]
7. Association between lipid-lowering agents with intervertebral disc degeneration, sciatica and low back pain: a drug-targeted mendelian randomized study and cross-sectional observation. Liu C; Chu X; Biao Y; Jin Q; Zhang Y; Gao Y; Feng S; Ma J; Zhang Y Lipids Health Dis; 2024 Oct; 23(1):327. PubMed ID: 39358768 [TBL] [Abstract][Full Text] [Related]
8. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504 [TBL] [Abstract][Full Text] [Related]
9. Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study. Cai G; Liu J; Cai M; Shao L Lipids Health Dis; 2024 Aug; 23(1):237. PubMed ID: 39090671 [TBL] [Abstract][Full Text] [Related]
10. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study. Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544 [TBL] [Abstract][Full Text] [Related]
11. Association between lipid-lowering drugs and allergic diseases: A Mendelian randomization study. Xu Y; Li Y World Allergy Organ J; 2024 Apr; 17(4):100899. PubMed ID: 38623319 [TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering drugs and inflammatory bowel disease's risk: a drug-target Mendelian randomization study. Zhao J; Chen R; Luo M; Gong H; Li K; Zhao Q Diabetol Metab Syndr; 2024 Jan; 16(1):12. PubMed ID: 38191425 [TBL] [Abstract][Full Text] [Related]
13. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer. Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363 [TBL] [Abstract][Full Text] [Related]
14. Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study. Zhang X; Geng T; Li N; Wu L; Wang Y; Zheng D; Guo B; Wang B Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615727 [TBL] [Abstract][Full Text] [Related]
15. Association of lipid-lowering drugs with the risk of type 2 diabetes and its complications: a mendelian randomized study. Zhang YY; Chen BX; Wan Q Diabetol Metab Syndr; 2024 Oct; 16(1):240. PubMed ID: 39367514 [TBL] [Abstract][Full Text] [Related]
16. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study. He JY; Zhang X; Wang K; Lv WQ J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717 [TBL] [Abstract][Full Text] [Related]
17. Association of lipid-lowering drugs with gut microbiota: A Mendelian randomization study. Shi L; Liu X; Li E; Zhang S; Zhou A J Clin Lipidol; 2024; 18(5):e797-e808. PubMed ID: 38971663 [TBL] [Abstract][Full Text] [Related]
18. Association of lipid-lowering drugs with risk of sarcopenia: a drug target mendelian randomization study and meta-analysis. Li J; Zang C; Lv H; Xiao Z; Li P; Xiao B; Zhou L Hum Genomics; 2024 Jul; 18(1):76. PubMed ID: 38961447 [TBL] [Abstract][Full Text] [Related]
19. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study. Miao L; Miao T; Zhang Y; Hao J BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735 [TBL] [Abstract][Full Text] [Related]
20. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study. Liang Z; Zhao L; Lou Y; Liu S QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]